With our baby boomer-in-chief turning 60 earlier this summer and the baby boom generation marking that same milestone this year, we're providing a number of articles that might be useful to this noteworthy generation. This article was first published on June 30, 2005.
The dynamics of drug consumption are in a continual state of flux. Businesses and governments are actively seeking to contain costs, and evidence suggests that they are succeeding. Recent data from the Centers for Medicare and Medicaid Services indicate that spending on prescription drugs increased 10.7% in 2003, compared with 14.9% in 2002, and other data suggest that the rate continues to ease lower.
Pharmacy benefit management companies (PBMs) like Medco (NYSE:MHS) and Express Scripts (NASDAQ:ESRX) have played a major role in keeping spending in check, in part by pushing generics. These companies have driven the switch from branded drugs to generics with behind-the-scenes actions such as encouraging doctors and pharmacists to provide patients with the lowest-cost medicines.
But there's also another, more direct method of containing costs: requiring higher co-payments.
A piece in The Wall Street Journal shows just how high co-payments could go. The report indicates that Georgia state employees now will have to pay as much as $100 if they want certain brand-name drugs. Among the drugs included in the priciest co-pay tier are Pfizer's (NYSE:PFE) Zoloft antidepressant and Wyeth's (NYSE:WYE) and King Pharmaceuticals' (NYSE:KG) blood-pressure treatment, Altace. In contrast, those same state employees can buy generics for just a $10 co-pay. And the state is not alone in its efforts: Almost 40% of all employers had co-pays exceeding $30 in 2005, versus 10% in 2001.
This is bad news for companies unlucky enough to have drugs not favored by benefit plans. It's hard to imagine consumers paying $30 to $100 if they have the option of paying just $10. Of course, makers of branded drugs aren't going to wither away, thanks to ongoing innovation. But investors also should expect the higher co-payment trend to boost major generic players like Teva Pharmaceutical (NASDAQ:TEVA), Mylan Laboratories, and Novartis (NYSE:NVS).
As the baby boomers reach retirement age, certain health-care and financial stocks are poised for growth. Our top analysts share their best stock picks in this special report: The Big Boom: Explosive Opportunities in Biotech and Health Stocks.
Pfizer is a recommendation of the Motley Fool Inside Value newsletter service.
Fool sector head Joey Khattab updated this article, which was written by Brian Gorman. Joey does not own shares in the companies mentioned. The Fool's disclosure policy is ageless.
